Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. more
Time Frame | NRIX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.02% | -2.06% | -0.55% |
1-Month Return | -7.11% | -1.92% | 2.72% |
3-Month Return | -18.19% | -10.4% | 7.66% |
6-Month Return | 9.76% | -4.6% | 10.15% |
1-Year Return | 124.89% | 4.06% | 27.53% |
3-Year Return | -27.71% | 1.94% | 32.31% |
5-Year Return | 6.47% | 36.48% | 89.2% |
Nov '19 | Nov '20 | Nov '21 | Nov '22 | Nov '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 31.11M | 17.82M | 29.75M | 38.63M | 76.99M | [{"date":"2019-11-30","value":40.42,"profit":true},{"date":"2020-11-30","value":23.15,"profit":true},{"date":"2021-11-30","value":38.64,"profit":true},{"date":"2022-11-30","value":50.17,"profit":true},{"date":"2023-11-30","value":100,"profit":true}] |
Cost of Revenue | 45.02M | 66.49M | 6.08M | 10.81M | 189.15M | [{"date":"2019-11-30","value":23.8,"profit":true},{"date":"2020-11-30","value":35.15,"profit":true},{"date":"2021-11-30","value":3.22,"profit":true},{"date":"2022-11-30","value":5.71,"profit":true},{"date":"2023-11-30","value":100,"profit":true}] |
Gross Profit | (13.91M) | 17.82M | 29.75M | 38.63M | (112.16M) | [{"date":"2019-11-30","value":-36.01,"profit":false},{"date":"2020-11-30","value":46.13,"profit":true},{"date":"2021-11-30","value":77.02,"profit":true},{"date":"2022-11-30","value":100,"profit":true},{"date":"2023-11-30","value":-290.37,"profit":false}] |
Gross Margin | (44.71%) | 100.00% | 100.00% | 100.00% | (145.69%) | [{"date":"2019-11-30","value":-44.71,"profit":false},{"date":"2020-11-30","value":100,"profit":true},{"date":"2021-11-30","value":100,"profit":true},{"date":"2022-11-30","value":100,"profit":true},{"date":"2023-11-30","value":-145.69,"profit":false}] |
Operating Expenses | 53.35M | 82.80M | 147.64M | 222.49M | 232.05M | [{"date":"2019-11-30","value":22.99,"profit":true},{"date":"2020-11-30","value":35.68,"profit":true},{"date":"2021-11-30","value":63.62,"profit":true},{"date":"2022-11-30","value":95.88,"profit":true},{"date":"2023-11-30","value":100,"profit":true}] |
Operating Income | (22.24M) | (64.98M) | (117.89M) | (183.87M) | (155.06M) | [{"date":"2019-11-30","value":-2223600000,"profit":false},{"date":"2020-11-30","value":-6498300000,"profit":false},{"date":"2021-11-30","value":-11788600000,"profit":false},{"date":"2022-11-30","value":-18386700000,"profit":false},{"date":"2023-11-30","value":-15506300000,"profit":false}] |
Total Non-Operating Income/Expense | 1.55M | 2.41M | 1.65M | 7.01M | 22.23M | [{"date":"2019-11-30","value":6.98,"profit":true},{"date":"2020-11-30","value":10.85,"profit":true},{"date":"2021-11-30","value":7.4,"profit":true},{"date":"2022-11-30","value":31.55,"profit":true},{"date":"2023-11-30","value":100,"profit":true}] |
Pre-Tax Income | (21.46M) | (63.78M) | (117.06M) | (180.36M) | (143.95M) | [{"date":"2019-11-30","value":-2146000000,"profit":false},{"date":"2020-11-30","value":-6377700000,"profit":false},{"date":"2021-11-30","value":-11706300000,"profit":false},{"date":"2022-11-30","value":-18036000000,"profit":false},{"date":"2023-11-30","value":-14394800000,"profit":false}] |
Income Taxes | 239.00K | (20.54M) | 131.00K | (14.31M) | 13.49M | [{"date":"2019-11-30","value":1.77,"profit":true},{"date":"2020-11-30","value":-152.27,"profit":false},{"date":"2021-11-30","value":0.97,"profit":true},{"date":"2022-11-30","value":-106.15,"profit":false},{"date":"2023-11-30","value":100,"profit":true}] |
Income After Taxes | (21.70M) | (43.24M) | (117.19M) | (166.04M) | (157.43M) | [{"date":"2019-11-30","value":-2169900000,"profit":false},{"date":"2020-11-30","value":-4324200000,"profit":false},{"date":"2021-11-30","value":-11719400000,"profit":false},{"date":"2022-11-30","value":-16604500000,"profit":false},{"date":"2023-11-30","value":-15743410500,"profit":false}] |
Income From Continuous Operations | (21.70M) | (43.24M) | (117.19M) | (180.36M) | (143.95M) | [{"date":"2019-11-30","value":-2169900000,"profit":false},{"date":"2020-11-30","value":-4324200000,"profit":false},{"date":"2021-11-30","value":-11719400000,"profit":false},{"date":"2022-11-30","value":-18036000000,"profit":false},{"date":"2023-11-30","value":-14394800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-11-30","value":"-","profit":true},{"date":"2020-11-30","value":"-","profit":true},{"date":"2021-11-30","value":"-","profit":true},{"date":"2022-11-30","value":"-","profit":true},{"date":"2023-11-30","value":"-","profit":true}] |
Net Income | (21.70M) | (43.24M) | (117.19M) | (166.04M) | (143.95M) | [{"date":"2019-11-30","value":-2169900000,"profit":false},{"date":"2020-11-30","value":-4324200000,"profit":false},{"date":"2021-11-30","value":-11719400000,"profit":false},{"date":"2022-11-30","value":-16604500000,"profit":false},{"date":"2023-11-30","value":-14394800000,"profit":false}] |
EPS (Diluted) | - | (4.10) | (2.73) | (3.73) | (2.65) | [{"date":"2019-11-30","value":"-","profit":true},{"date":"2020-11-30","value":-410,"profit":false},{"date":"2021-11-30","value":-273,"profit":false},{"date":"2022-11-30","value":-373,"profit":false},{"date":"2023-11-30","value":-265,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NRIX | |
---|---|
Cash Ratio | 5.19 |
Current Ratio | 5.28 |
Quick Ratio | 5.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NRIX | |
---|---|
ROA (LTM) | -29.46% |
ROE (LTM) | -57.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NRIX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NRIX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 26.13 |
P/B | 3.91 |
Price/FCF | NM |
EV/R | 18.67 |
EV/Ebitda | NM |
Nurix Therapeutics Inc (NRIX) share price today is $20.24
Yes, Indians can buy shares of Nurix Therapeutics Inc (NRIX) on Vested. To buy Nurix Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NRIX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Nurix Therapeutics Inc (NRIX) via the Vested app. You can start investing in Nurix Therapeutics Inc (NRIX) with a minimum investment of $1.
You can invest in shares of Nurix Therapeutics Inc (NRIX) via Vested in three simple steps:
The 52-week high price of Nurix Therapeutics Inc (NRIX) is $29.56. The 52-week low price of Nurix Therapeutics Inc (NRIX) is $7.65.
The price-to-earnings (P/E) ratio of Nurix Therapeutics Inc (NRIX) is
The price-to-book (P/B) ratio of Nurix Therapeutics Inc (NRIX) is 3.91
The dividend yield of Nurix Therapeutics Inc (NRIX) is 0.00%
The market capitalization of Nurix Therapeutics Inc (NRIX) is $1.47B
The stock symbol (or ticker) of Nurix Therapeutics Inc is NRIX